Restylane Lyft with Lidocaine
Q-Med AB · Decision date Dec 23, 2025
What did the FDA approve?
FDA records P040024/S146 as a supplement to PMA P040024, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 23, 2025.
FDA approval order statement
Approval for the postapproval study (PAS) protocol submitted to comply with the conditions of approval outlined in the approval order for P040024/S142.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 23, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P040024/S146
- Regulatory pathway
- PMA supplement
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Dec 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040024/S144 · Related supplement
Restylane Injectable Gel
P040024/S142 · Related supplement
Restylane Lyft with Lidocaine
P040024/S146 received
Application receipt date recorded by FDA.
P040024/S146 · FDA decision
Normal 180 Day Track No User Fee
P040024/S143 · Related supplement
Restylane-L 1 mL; Restylane Lyft with Lidocaine 1 mL; Restylane Eyelight 0.5 mL
P040024/S147 · Related supplement
Restylane Lyft with Lidocaine
P040024/S148 · Related supplement
RESTYLANE INJECTABLE GEL
Timeline entries are records held by MedtechLedger for P040024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Restylane Injectable GelP040024/S144 | Q-Med AB | PMA supplement | Sep 26, 2025 | FDA |
Restylane Lyft with LidocaineP040024/S142 | Q-Med AB | PMA supplement | Nov 4, 2025 | FDA |
| Q-Med AB | PMA supplement | Jan 29, 2026 | FDA | |
Restylane Lyft with LidocaineP040024/S147 | Q-Med AB | PMA supplement | Feb 5, 2026 | FDA |
RESTYLANE INJECTABLE GELP040024/S148 | Q-Med AB | PMA supplement | Mar 12, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, SE-752-28
Sources and methodology
- Original FDA record: P040024/S146
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





